ストックスクリーナーアプリを入手
27.70
0.36%
-0.10
アフターアワーズ：
27.70
前日終値:
$27.80
開ける：
$27.71
24時間の取引高:
20.86M
Relative Volume:
3.02
時価総額：
$19.82B
収益：
$13.31M
当期純損益:
$-1.01B
株価収益率:
-23.71
EPS:
-1.1685
ネットキャッシュフロー:
$-766.86M
1週間 パフォーマンス:
-1.28%
1か月 パフォーマンス:
+2.03%
6か月 パフォーマンス:
+84.18%
1年 パフォーマンス:
+152.51%
1日の値動き範囲:
$27.12
$27.96
1週間の範囲:
$27.12
$28.95
52週間の値動き範囲:
$8.73
$30.33
Roivant Sciences Ltd Stock (ROIV) Company Profile
Compare ROIV vs VRTX, REGN, ALNY, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
27.70 | 19.90B | 13.31M | -1.01B | -766.86M | -1.1685 |
VRTX
Vertex Pharmaceuticals Inc
|
454.00 | 116.36B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
732.87 | 77.96B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
312.17 | 41.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
663.93 | 42.36B | 4.16B | 1.29B | 734.26M | 19.59 |
ONC
Beone Medicines Ltd Adr
|
275.28 | 31.38B | 5.36B | 287.73M | 924.18M | 2.5229 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-02 | 開始されました | Citigroup | Buy |
| 2025-07-10 | 再開されました | Goldman | Buy |
| 2024-02-15 | 開始されました | Wolfe Research | Outperform |
| 2024-01-05 | 開始されました | Piper Sandler | Overweight |
| 2023-12-12 | 開始されました | Deutsche Bank | Buy |
| 2023-10-17 | 開始されました | Guggenheim | Buy |
| 2023-06-08 | 開始されました | BofA Securities | Neutral |
| 2022-10-27 | 開始されました | JP Morgan | Overweight |
| 2022-05-23 | 開始されました | SVB Leerink | Outperform |
| 2022-04-29 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-12-15 | 開始されました | Goldman | Buy |
| 2021-11-08 | 開始されました | H.C. Wainwright | Buy |
| 2021-10-28 | 開始されました | Citigroup | Buy |
| 2021-10-26 | 開始されました | Cowen | Outperform |
| 2021-10-26 | 開始されました | Jefferies | Buy |
| 2021-10-26 | 開始されました | Truist | Buy |
すべてを表示
Roivant Sciences Ltd (ROIV) 最新ニュース
Bernstein initiates Roivant Sciences stock with outperform rating - Investing.com
Sanford C. Bernstein Begins Coverage on Roivant Sciences (NASDAQ:ROIV) - MarketBeat
Roivant Sciences Insider Sold Shares Worth $5,648,000, According to a Recent SEC Filing - marketscreener.com
Roivant Sciences (NASDAQ:ROIV) CEO Sells 200,000 Shares - MarketBeat
Roivant (NASDAQ: ROIV) president exercises 200K options and sells 200K shares - Stock Titan
Trade Recap: What is the dividend yield of Roivant Sciences LtdShort Setup & AI Based Trade Execution Alerts - baoquankhu1.vn
Roivant Sciences Insider Sold Shares Worth $1,200,573, According to a Recent SEC Filing - marketscreener.com
Insider Sell Alert: Melissa Epperly Sells 41,861 Shares of Roiva - GuruFocus
Roivant Sciences (NASDAQ:ROIV) Director Melissa Epperly Sells 41,861 Shares - MarketBeat
Roivant Sciences (ROIV) director sells 41,861 common shares - Stock Titan
Roivant secures FDA priority review for dermatomyositis treatment - MSN
Aug Catalysts: Can Roivant Sciences Ltd outperform under higher oil prices2026 PreEarnings & Growth Oriented Trade Recommendations - baoquankhu1.vn
Rockefeller Financial files to sell 200,000 Roivant shares | ROIV SEC FilingForm 144 - Stock Titan
Aug Reactions: Is Roivant Sciences Ltd stock undervalued right nowWeekly Stock Recap & Expert Curated Trade Setup Alerts - baoquankhu1.vn
Bamco Inc. NY Acquires 105,000 Shares in Roivant Sciences Ltd. - National Today
105,000 Shares in Roivant Sciences Ltd. $ROIV Acquired by Bamco Inc. NY - MarketBeat
Do You Believe in the Growth Prospects of Roivant Sciences Ltd. (ROIV)? - MSN
Roivant Sciences Ltd. $ROIV Shares Purchased by HighVista Strategies LLC - MarketBeat
Roivant Sciences Ltd. $ROIV is Foursixthree Capital LP's 7th Largest Position - MarketBeat
Roivant Sciences Ltd. $ROIV Shares Sold by Prosight Management LP - MarketBeat
Roivant Sciences Ltd. $ROIV Shares Bought by Integral Health Asset Management LLC - MarketBeat
Roivant Sciences Ltd. (ROIV) Discusses $2.25 Billion Global Settlement Resolving COVID Vaccine Patent LitigationSlideshow (NASDAQ:ROIV) 2026-03-13 - Seeking Alpha
Roivant Sciences stock hits all-time high at 30.31 USD - Investing.com Nigeria
Roivant Sciences Hits New 52-Week High at $30.30, Up 180.72% - Markets Mojo
Roivant Sciences stock hits all-time high at 30.31 USD By Investing.com - Investing.com Canada
Leerink Partners maintains Roivant Sciences (ROIV) outperform recommendation - MSN
Roivant at Leerink Conference: Strategic Transformation Insights - Investing.com Australia
Dimensional Fund Advisors LP Has $140.84 Million Stake in Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant Sciences (NASDAQ:ROIV) Reaches New 52-Week HighHere's Why - MarketBeat
(ROIV) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Roivant Sciences stock hits all-time high at 29.23 USD - Investing.com Nigeria
WINTON GROUP Ltd Purchases 335,269 Shares of Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant Sciences (ROIV) Gets a Buy from H.C. Wainwright - The Globe and Mail
Aug Rallies: Can Roivant Sciences Ltd. sustain earnings growthQuarterly Portfolio Report & Free Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Roivant Sciences Hits New 52-Week High at $29.20, Up 170.89% - Markets Mojo
Dow Update: Can Roivant Sciences Ltd outperform under higher oil pricesJuly 2025 Intraday Action & Weekly High Return Forecasts - baoquankhu1.vn
Neo Ivy Capital Management Has $3.59 Million Stake in Roivant Sciences Ltd. $ROIV - MarketBeat
Blue Owl Capital Holdings LP Acquires New Holdings in Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant Sciences Ltd. (ROIV) reports Q3 loss, misses revenue estimates - MSN
Sentiment Review: Is Roivant Sciences Ltd stock undervalued right nowGap Up & Low Risk High Reward Ideas - baoquankhu1.vn
Roivant Sciences Ltd. Experiences Revision in Stock Evaluation Amid Strong Market Performance - Markets Mojo
HC Wainwright Expects Stronger Earnings for Roivant Sciences - MarketBeat
9 Biotech Stocks Trading Far Below Fair Value With Up to 250% Upside Potential - Investing.com
Roivant Sciences Hits New 52-Week High at $29.82, Up 179% - Markets Mojo
Roivant Sciences Hits Day High with Strong 6% Intraday Surge - Markets Mojo
Cowen Maintains Buy on Roivant Sciences Ltd (ROIV) March 2026 - Meyka
Roivant Sciences stock hits all-time high at 29.23 USD By Investing.com - Investing.com Canada
H.C. Wainwright raises Roivant Sciences stock price target to $34 on settlement proceeds By Investing.com - Investing.com South Africa
A Look At Roivant Sciences (ROIV) Valuation After Recent Share Price Strength - Yahoo Finance
Key facts: Roivant Sciences secures $2.25B settlement; boosts buyback to $1B; price target raised to $34 - TradingView
Moderna to pay up to $2.25B to settle COVID-19 patents case - BioWorld MedTech
Roivant Sciences Ltd (ROIV) 財務データ
収益
当期純利益
現金流量
EPS
Roivant Sciences Ltd (ROIV) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Venker Eric | President & Immunovant CEO |
Mar 17 '26 |
Sale |
28.24 |
200,000 |
5,648,000 |
1,647,546 |
| Epperly Melissa B, | Director |
Mar 16 '26 |
Sale |
28.68 |
41,861 |
1,200,573 |
15,804 |
0.37%
大文字化:
|
ボリューム (24 時間):